AbbVie snags another preclinical Parkinson's program with $17M Caraway pact

Caraway Therapeutics wasn’t going to partner off its Parkinson’s program for a few more years, but AbbVie came along with an offer it couldn’t refuse.

“The deal we got was as good as we had gotten if we had held onto the program for two, three, four years … The deal was nice enough to persuade us to do it now,” said Caraway CEO Martin Williams, adding that the biotech had talked to about 15 companies about potential partnerships.